Status:
COMPLETED
Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism
Lead Sponsor:
University of Southern Denmark
Collaborating Sponsors:
H. Lundbeck A/S
Conditions:
Healthy
Eligibility:
All Genders
18-45 years
Phase:
PHASE4
Brief Summary
To study the impact of CYP2C19 polymorphism on escitalopram pharmacokinetics and pharmacodynamics measured as changes in pupil diameter
Detailed Description
Escitalopram, the therapeutic active S-enantiomer of citalopram, is a selective serotonine reuptake inhibitor (SSRI) used for treatment of depression and anxiety disorders. The antidepressant effect i...
Eligibility Criteria
Inclusion
- Healthy volunteer
- Age: 18-45 years
- Phenotyped for CYP2C19 activity
Exclusion
- Drug or alcohol abuse
- Allergy towards escitalopram
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2007
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00397059
Start Date
December 1 2006
End Date
October 1 2007
Last Update
February 6 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Pharmacology, University of Southern Denmark
Odense, Denmark, DK-5000